The efficacy of the mTOR inhibitor sirolimus, and targeted therapies that block the Ras/BRAF/MEK/ERK1/2 and PI3KCA/AKT/mTOR pathways in cancer and complex VAs, further supports a role of ESC-like cells in the pathogenesis of these conditions. This evidence concerns the gene MAP2K7 and cancer.